Great article from Gavin Giannoni on this topic. Applies to Kesimpta and rituximab as well. If you have Substack, you can read for free. https://open.substack.com/pub/gavingiovannoni/p/serious-infections-on-anti-cd20-therapies?r=2f3ys&utm_medium=ios Bottom line - there is a 7% risk of serious infection with Ocrevus and similar meds in general population. More if you’re older, more disabled or have other comorbidities, less if you are none of those things. But this paragraph is great to read - “This data on serious infections on ocrelizumab needs to be balanced against the long-term benefits of being on ocrelizumab. We presented the long-term follow-up data at ECTRIMS, i.e. after 11 years of continuous ocrelizumab treatment, ocrelizumab effectively controlled long-term disease activity and prevented disability accumulation. Three-quarters of pwRMS were progression-free, and >90% did not need a walking aid. A third of pwPPMS were progression-free, and 80% did not need a wheelchair. Although these results only represent the results of pwMS staying on ocrelizumab, they are impressive and indicate how anti-CD20 therapies have changed the long-term outcome for people with MS.”